US Pharma MarketingThe post FDA clears C2N Diagnostics’ early Alzheimer’s assessment test appeared first on Medical Device Network.
FDA clears C2N Diagnostics’ early Alzheimer’s assessment test
C2N’s Alzheimer’s test is the first to be FDA-cleared for use in patients as young as 40 who present with cognitive impairment symptoms. The post FDA clears C2N Diagnostics’ early Alzheimer’s assessment test appeared first on Medical Device Network .
C2N’s Alzheimer’s test is the first to be FDA-cleared for use in patients as young as 40 who present with cognitive impairment symptoms.
Source: Medical Device Network